Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Diseases

  Free Subscription

Articles published in Gut

Retrieve available abstracts of 94 articles:
HTML format
Text format

Single Articles

    October 2018
  1. ZHAO Y, Shuen TWH, Toh TB, Chan XY, et al
    Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.
    Gut. 2018;67:1845-1854.
    PubMed     Text format     Abstract available

  2. FERNANDEZ J, Acevedo J, Wiest R, Gustot T, et al
    Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis.
    Gut. 2018;67:1870-1880.
    PubMed     Text format     Abstract available

    September 2018
  3. CANI PD
    Human gut microbiome: hopes, threats and promises.
    Gut. 2018;67:1716-1725.
    PubMed     Text format     Abstract available

    August 2018
  4. MONTAGNER A, Le Cam L, Guillou H
    beta-catenin oncogenic activation rewires fatty acid catabolism to fuel hepatocellular carcinoma.
    Gut. 2018 Aug 4. pii: gutjnl-2018-316557. doi: 10.1136/gutjnl-2018-316557.
    PubMed     Text format    

    Lipid-rich environment: a key role promoting carcinogenesis in obesity-related non-alcoholic fatty liver disease.
    Gut. 2018;67:1376-1377.
    PubMed     Text format    

  6. FUJIWARA N, Nakagawa H, Enooku K, Kudo Y, et al
    CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.
    Gut. 2018;67:1493-1504.
    PubMed     Text format     Abstract available

  7. STRNAD P, Buch S, Hamesch K, Fischer J, et al
    Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.
    Gut. 2018 Aug 1. pii: gutjnl-2018-316228. doi: 10.1136/gutjnl-2018-316228.
    PubMed     Text format     Abstract available

    July 2018
  8. REN Z, Li A, Jiang J, Zhou L, et al
    Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
    Gut. 2018 Jul 25. pii: gutjnl-2017-315084. doi: 10.1136/gutjnl-2017-315084.
    PubMed     Text format     Abstract available

  9. LIM CJ, Lee YH, Pan L, Lai L, et al
    Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Gut. 2018 Jul 3. pii: gutjnl-2018-316510. doi: 10.1136/gutjnl-2018-316510.
    PubMed     Text format     Abstract available

  10. ROTMAN Y, Sanyal AJ
    Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus-authors' response.
    Gut. 2018;67:1372.
    PubMed     Text format    

  11. CUSI K
    Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus.
    Gut. 2018;67:1371.
    PubMed     Text format    

    June 2018
  12. BERNSMEIER C, Triantafyllou E, Brenig R, Lebosse FJ, et al
    CD14(+) CD15(-) HLA-DR(-) myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure.
    Gut. 2018;67:1155-1167.
    PubMed     Text format     Abstract available

    May 2018
  13. GRETEN TF, Korangy F
    CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC.
    Gut. 2018;67:783-784.
    PubMed     Text format    

  14. GAO B, Ma J, Xiang X
    MAIT cells: a novel therapeutic target for alcoholic liver disease?
    Gut. 2018;67:784-786.
    PubMed     Text format    

  15. RIVA A, Patel V, Kurioka A, Jeffery HC, et al
    Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease.
    Gut. 2018;67:918-930.
    PubMed     Text format     Abstract available

  16. GRANDER C, Adolph TE, Wieser V, Lowe P, et al
    Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease.
    Gut. 2018;67:891-901.
    PubMed     Text format     Abstract available

    April 2018
  17. SENNI N, Savall M, Cabrerizo Granados D, Alves-Guerra MC, et al
    beta-catenin-activated hepatocellular carcinomas are addicted to fatty acids.
    Gut. 2018 Apr 12. pii: gutjnl-2017-315448. doi: 10.1136/gutjnl-2017-315448.
    PubMed     Text format     Abstract available

  18. Correction: Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis.
    Gut. 2018;67:782.
    PubMed     Text format    

    March 2018
  19. HIRSCHFIELD GM, Dyson JK, Alexander GJM, Chapman MH, et al
    The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
    Gut. 2018 Mar 28. pii: gutjnl-2017-315259. doi: 10.1136/gutjnl-2017-315259.
    PubMed     Text format     Abstract available

    Diagnosis of hepatocellular carcinoma with MRI.
    Gut. 2018 Mar 16. pii: gutjnl-2018-315999. doi: 10.1136/gutjnl-2018-315999.
    PubMed     Text format    

  21. Correction: Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.
    Gut. 2018;67:594.
    PubMed     Text format    

  22. LUETKENS JA, Klein S, Traeber F, Schmeel FC, et al
    Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study.
    Gut. 2018;67:593-594.
    PubMed     Text format    

  23. HESSMANN E, Patzak MS, Klein L, Chen N, et al
    Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.
    Gut. 2018;67:497-507.
    PubMed     Text format     Abstract available

  24. SAMSON A, Bentham MJ, Scott K, Nuovo G, et al
    Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.
    Gut. 2018;67:562-573.
    PubMed     Text format     Abstract available

    February 2018
  25. HEO MJ, Kim TH, You JS, Blaya D, et al
    Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression.
    Gut. 2018 Feb 23. pii: gutjnl-2017-315123. doi: 10.1136/gutjnl-2017-315123.
    PubMed     Text format     Abstract available

  26. CHEW V, Lee YH, Pan L, Nasir NJM, et al
    Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma.
    Gut. 2018 Feb 13. pii: gutjnl-2017-315485. doi: 10.1136/gutjnl-2017-315485.
    PubMed     Text format     Abstract available

  27. RENZULLI M, Biselli M, Brocchi S, Granito A, et al
    New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm.
    Gut. 2018 Feb 3. pii: gutjnl-2017-315384. doi: 10.1136/gutjnl-2017-315384.
    PubMed     Text format     Abstract available

  28. LEE JH, Suh JH, Choi SY, Kang HJ, et al
    Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis.
    Gut. 2018 Feb 2. pii: gutjnl-2017-315348. doi: 10.1136/gutjnl-2017-315348.
    PubMed     Text format     Abstract available

  29. PUENGEL T, Tacke F
    Repair macrophages in acute liver failure.
    Gut. 2018;67:202-203.
    PubMed     Text format    

  30. EFERL R, Trauner M
    Chromosomal instability in HCC: a key function for checkpoint kinase 2.
    Gut. 2018;67:204-205.
    PubMed     Text format    

    January 2018
  31. PERUGORRIA MJ, Esparza-Baquer A, Oakley F, Labiano I, et al
    Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage.
    Gut. 2018 Jan 27. pii: gutjnl-2017-314107. doi: 10.1136/gutjnl-2017-314107.
    PubMed     Text format     Abstract available

  32. IBRAHIM SH, Hirsova P, Gores GJ
    Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315691. doi: 10.1136/gutjnl-2017-315691.
    PubMed     Text format     Abstract available

  33. CHEN CJ
    Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315407. doi: 10.1136/gutjnl-2017-315407.
    PubMed     Text format    

  34. BANTEL H, Canbay A
    Loss of KRAS control as consequence of downregulated microRNA-622 in hepatocellular carcinoma and its potential therapeutic implication.
    Gut. 2018 Jan 20. pii: gutjnl-2017-315630. doi: 10.1136/gutjnl-2017-315630.
    PubMed     Text format    

  35. YIGIT B, Boyle M, Ozler O, Erden N, et al
    Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis.
    Gut. 2018 Jan 20. pii: gutjnl-2017-315668. doi: 10.1136/gutjnl-2017-315668.
    PubMed     Text format    

  36. PERNES G, Lancaster GI, Murphy AJ
    Take me to the liver: adipose tissue macrophages coordinate hepatic neutrophil recruitment.
    Gut. 2018 Jan 3. pii: gutjnl-2017-315393. doi: 10.1136/gutjnl-2017-315393.
    PubMed     Text format    

  37. NEWSOME PN, Cramb R, Davison SM, Dillon JF, et al
    Guidelines on the management of abnormal liver blood tests.
    Gut. 2018;67:6-19.
    PubMed     Text format     Abstract available

  38. WIESER V, Adolph TE, Grander C, Grabherr F, et al
    Adipose type I interferon signalling protects against metabolic dysfunction.
    Gut. 2018;67:157-165.
    PubMed     Text format     Abstract available

    December 2017
  39. DIETRICH P, Koch A, Fritz V, Hartmann A, et al
    Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Gut. 2017 Dec 23. pii: gutjnl-2017-315402. doi: 10.1136/gutjnl-2017-315402.
    PubMed     Text format     Abstract available

  40. CUI CP, Wong CC, Kai AK, Ho DW, et al
    SENP1 promotes hypoxia-induced cancer stemness by HIF-1alpha deSUMOylation and SENP1/HIF-1alpha positive feedback loop.
    Gut. 2017;66:2149-2159.
    PubMed     Text format     Abstract available

  41. CONIGLIARO A, Tripodi M, Parola M
    SENP1 activity sustains cancer stem cell in hypoxic HCC.
    Gut. 2017;66:2051-2052.
    PubMed     Text format    

    November 2017
  42. GERBES A, Zoulim F, Tilg H, Dufour JF, et al
    Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.
    Gut. 2017 Nov 17. pii: gutjnl-2017-315068. doi: 10.1136/gutjnl-2017-315068.
    PubMed     Text format     Abstract available

    October 2017
  43. MAZARD T, Boonsirikamchai P, Overman MJ, Asran MA, et al
    Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
    Gut. 2017 Oct 30. pii: gutjnl-2017-313786. doi: 10.1136/gutjnl-2017-313786.
    PubMed     Text format     Abstract available

  44. BIJNEN M, Josefs T, Cuijpers I, Maalsen CJ, et al
    Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice.
    Gut. 2017 Oct 26. pii: gutjnl-2016-313654. doi: 10.1136/gutjnl-2016-313654.
    PubMed     Text format     Abstract available

  45. KIM GA, Lim YS, Han S, Choi J, et al
    High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Gut. 2017 Oct 21. pii: gutjnl-2017-314904. doi: 10.1136/gutjnl-2017-314904.
    PubMed     Text format     Abstract available

  46. BROWN PM, Rotman Y
    What if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liver.
    Gut. 2017;66:1732-1733.
    PubMed     Text format    

    September 2017
  47. LV Y, Qi X, He C, Wang Z, et al
    Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial.
    Gut. 2017 Sep 28. pii: gutjnl-2017-314634. doi: 10.1136/gutjnl-2017-314634.
    PubMed     Text format     Abstract available

  48. ZHOU J, Liu M, Sun H, Feng Y, et al
    Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
    Gut. 2017 Sep 22. pii: gutjnl-2017-314032. doi: 10.1136/gutjnl-2017-314032.
    PubMed     Text format     Abstract available

  49. MUELLER C, Waldburger N, Stampfl U, Kauczor HU, et al
    Non-invasive diagnosis of hepatocellular carcinoma revisited.
    Gut. 2017 Sep 12. pii: gutjnl-2017-314981. doi: 10.1136/gutjnl-2017-314981.
    PubMed     Text format    

  50. KIM W, Khan SK, Liu Y, Xu R, et al
    Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma.
    Gut. 2017 Sep 2. pii: gutjnl-2017-314061. doi: 10.1136/gutjnl-2017-314061.
    PubMed     Text format     Abstract available

  51. Erratum: The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2017;66:1730.
    PubMed     Text format    

  52. BEDOSSA P, Tordjman J, Aron-Wisnewsky J, Poitou C, et al
    Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity.
    Gut. 2017;66:1688-1696.
    PubMed     Text format     Abstract available

  53. MAGDALENO F, Trebicka J
    Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression.
    Gut. 2017;66:1540-1541.
    PubMed     Text format    

    August 2017
  54. PIANO S, Bartoletti M, Tonon M, Baldassarre M, et al
    Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections.
    Gut. 2017 Aug 31. pii: gutjnl-2017-314324. doi: 10.1136/gutjnl-2017-314324.
    PubMed     Text format     Abstract available

  55. JIAO N, Baker SS, Chapa-Rodriguez A, Liu W, et al
    Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.
    Gut. 2017 Aug 3. pii: gutjnl-2017-314307. doi: 10.1136/gutjnl-2017-314307.
    PubMed     Text format     Abstract available

  56. HO DWH, Chan LK, Chiu YT, Xu IMJ, et al
    TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication.
    Gut. 2017;66:1496-1506.
    PubMed     Text format     Abstract available

  57. BERASAIN C, Lechel A
    Targeting the correct target in HCC.
    Gut. 2017;66:1352-1354.
    PubMed     Text format    

    July 2017
  58. XIANG DM, Sun W, Ning BF, Zhou TF, et al
    The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis.
    Gut. 2017 Jul 28. pii: gutjnl-2016-313392. doi: 10.1136/gutjnl-2016-313392.
    PubMed     Text format     Abstract available

  59. CORRAL JE, Mousa OY, Riegert-Johnson DL
    Massive gastrointestinal bleeding after transjugular intrahepatic portosystemic shunt (TIPS).
    Gut. 2017 Jul 7. pii: gutjnl-2017-314254. doi: 10.1136/gutjnl-2017-314254.
    PubMed     Text format    

  60. ALBANO E, Stickel F
    Targeting toll-like receptor 7/8 improves host anti-infective response in alcoholic cirrhosis.
    Gut. 2017 Jul 7. pii: gutjnl-2017-314437. doi: 10.1136/gutjnl-2017-314437.
    PubMed     Text format    

  61. HARDY T, Zeybel M, Day CP, Dipper C, et al
    Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.
    Gut. 2017;66:1321-1328.
    PubMed     Text format     Abstract available

  62. CALVISI D, Eferl R
    CDK4/6 inhibition and sorafenib: a menage a deux in HCC therapy?
    Gut. 2017;66:1179-1180.
    PubMed     Text format    

  63. MANDORFER M, Peck-Radosavljevic M, Reiberger T
    Prevention of progression from small to large varices: are we there yet? An updated meta-analysis.
    Gut. 2017;66:1347-1349.
    PubMed     Text format    

    June 2017
  64. ROLAS L, Boussif A, Weiss E, Letteron P, et al
    NADPH oxidase depletion in neutrophils from patients with cirrhosis and restoration via toll-like receptor 7/8 activation.
    Gut. 2017 Jun 10. pii: gutjnl-2016-313443. doi: 10.1136/gutjnl-2016-313443.
    PubMed     Text format     Abstract available

  65. JIANG RY, Yang L
    The role of hepatokines in NAFLD-related extrahepatic diseases: culprit or accomplice?
    Gut. 2017 Jun 10. pii: gutjnl-2017-314411. doi: 10.1136/gutjnl-2017-314411.
    PubMed     Text format    

  66. LYU N, Lin Y, Kong Y, Zhang Z, et al
    FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut. 2017 Jun 7. pii: gutjnl-2017-314138. doi: 10.1136/gutjnl-2017-314138.
    PubMed     Text format    

  67. WANG Z, Zhang H, Han J, Wu MC, et al
    High body mass index and the risk of hepatocellular carcinoma.
    Gut. 2017 Jun 7. pii: gutjnl-2017-314259. doi: 10.1136/gutjnl-2017-314259.
    PubMed     Text format    

  68. BAJAJ JS, Liu EJ, Kheradman R, Fagan A, et al
    Fungal dysbiosis in cirrhosis.
    Gut. 2017 Jun 3. pii: gutjnl-2016-313170. doi: 10.1136/gutjnl-2016-313170.
    PubMed     Text format     Abstract available

  69. KULLAK-UBLICK GA, Andrade RJ, Merz M, End P, et al
    Drug-induced liver injury: recent advances in diagnosis and risk assessment.
    Gut. 2017;66:1154-1164.
    PubMed     Text format     Abstract available

  70. ADAMS LA, Anstee QM, Tilg H, Targher G, et al
    Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
    Gut. 2017;66:1138-1153.
    PubMed     Text format     Abstract available

  71. BROOKS AJ, Smith PJ, Cohen R, Collins P, et al
    UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care.
    Gut. 2017;66:988-1000.
    PubMed     Text format     Abstract available

    May 2017
  72. PANKOWICZ FP, Jarrett KE, Lagor WR, Bissig KD, et al
    CRISPR/Cas9: at the cutting edge of hepatology.
    Gut. 2017 May 9. pii: gutjnl-2016-313565. doi: 10.1136/gutjnl-2016-313565.
    PubMed     Text format     Abstract available

  73. THOMAS E
    Hepatitis B virus X protein: TRIMming antiviral defences in hepatocytes.
    Gut. 2017 May 5. pii: gutjnl-2017-314013. doi: 10.1136/gutjnl-2017-314013.
    PubMed     Text format    

  74. BREITKOPF-HEINLEIN K, Meyer C, Konig C, Gaitantzi H, et al
    BMP-9 interferes with liver regeneration and promotes liver fibrosis.
    Gut. 2017;66:939-954.
    PubMed     Text format     Abstract available

    April 2017
  75. TRIANTAFYLLOU E, Pop OT, Possamai LA, Wilhelm A, et al
    MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure.
    Gut. 2017 Apr 27. pii: gutjnl-2016-313615. doi: 10.1136/gutjnl-2016-313615.
    PubMed     Text format     Abstract available

  76. ALLWEISS L, Volz T, Giersch K, Kah J, et al
    Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
    Gut. 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162.
    PubMed     Text format     Abstract available

  77. HANIN G, Yayon N, Tzur Y, Haviv R, et al
    miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression.
    Gut. 2017 Apr 5. pii: gutjnl-2016-312869. doi: 10.1136/gutjnl-2016-312869.
    PubMed     Text format     Abstract available

  78. LI M, He Y, Zhou Z, Ramirez T, et al
    MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47phox-oxidative stress pathway in neutrophils.
    Gut. 2017;66:705-715.
    PubMed     Text format     Abstract available

  79. HUR K, Toiyama Y, Okugawa Y, Ide S, et al
    Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer.
    Gut. 2017;66:654-665.
    PubMed     Text format     Abstract available

  80. WANG S, Ding WX
    A small RNA in neutrophils protects against acute-on-chronic alcoholic liver injury.
    Gut. 2017;66:565-566.
    PubMed     Text format    

    March 2017
  81. CARLONI V, Lulli M, Madiai S, Mello T, et al
    CHK2 overexpression and mislocalisation within mitotic structures enhances chromosomal instability and hepatocellular carcinoma progression.
    Gut. 2017 Mar 30. pii: gutjnl-2016-313114. doi: 10.1136/gutjnl-2016-313114.
    PubMed     Text format     Abstract available

  82. HAGSTROM H, Tynelius P, Rasmussen F
    High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men.
    Gut. 2017 Mar 20. pii: gutjnl-2016-313622. doi: 10.1136/gutjnl-2016-313622.
    PubMed     Text format     Abstract available

  83. PARSEUS A, Sommer N, Sommer F, Caesar R, et al
    Microbiota-induced obesity requires farnesoid X receptor.
    Gut. 2017;66:429-437.
    PubMed     Text format     Abstract available

    February 2017
  84. SINN DH, Kang D, Chang Y, Ryu S, et al
    Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study.
    Gut. 2017;66:323-329.
    PubMed     Text format     Abstract available

    Non-alcoholic fatty liver disease as driving force in coronary heart disease?
    Gut. 2017;66:213-214.
    PubMed     Text format    

    January 2017
  86. ROTMAN Y, Sanyal AJ
    Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
    Gut. 2017;66:180-190.
    PubMed     Text format     Abstract available

  87. LI X, Yao W, Yuan Y, Chen P, et al
    Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Gut. 2017;66:157-167.
    PubMed     Text format     Abstract available

  88. AUGUSTIN S, Pons M, Genesca J
    Ruling in and ruling out with elastography in compensated advanced chronic liver disease.
    Gut. 2017;66:197-198.
    PubMed     Text format    

    September 2016
  89. SINGH A, Smith PJ, Cropley IM, Planche KL, et al
    Gallstone mimicry: a rare cause of abdominal pain.
    Gut. 2016 Sep 29. pii: gutjnl-2016-312706. doi: 10.1136/gutjnl-2016-312706.
    PubMed     Text format    

    July 2016
  90. GRILLET F, Bayet E, Villeronce O, Zappia L, et al
    Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture.
    Gut. 2016 Jul 25. pii: gutjnl-2016-311447. doi: 10.1136/gutjnl-2016-311447.
    PubMed     Text format     Abstract available

    March 2016
  91. GRIESMANN H, Drexel C, Milosevic N, Sipos B, et al
    Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer.
    Gut. 2016 Mar 24. pii: gutjnl-2015-310049. doi: 10.1136/gutjnl-2015-310049.
    PubMed     Text format     Abstract available

    February 2016
  92. EHLKEN H, Wroblewski R, Corpechot C, Arrive L, et al
    Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis.
    Gut. 2016 Feb 26. pii: gutjnl-2016-311452. doi: 10.1136/gutjnl-2016-311452.
    PubMed     Text format    

  93. COLOMBEL JF, Sands BE, Rutgeerts P, Sandborn W, et al
    The safety of vedolizumab for ulcerative colitis and Crohn's disease.
    Gut. 2016 Feb 18. pii: gutjnl-2015-311079. doi: 10.1136/gutjnl-2015-311079.
    PubMed     Text format     Abstract available

    September 2015
  94. KLEIN S, Rick J, Lehmann J, Schierwagen R, et al
    Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
    Gut. 2015 Sep 17. pii: gutjnl-2015-309600. doi: 10.1136/gutjnl-2015-309600.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.